Merus N.V., a biotechnology company specializing in innovative oncology treatments, has announced the launch of a public offering of its common shares. All shares will be offered by Merus, with the company planning to provide underwriters a 30-day option to purchase up to an additional 15% of the offered shares. The offering is contingent upon market and other conditions, and there is no assurance regarding the timing, size, or terms of completion. Merus is known for developing multispecific full-length antibodies and antibody-drug conjugates, including Biclonics®, Triclonics®, and ADClonics®.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.